yingweiwo

NAD+

Alias: β-DPNNSC-20272; Nadide; NSC 20272; NSC20272; beta-NAD; beta NAD; Enzopride Nadida; Codehydrase I; nadide; 53-84-9; NAD+; coenzyme I; beta-NAD; Codehydrogenase I; diphosphopyridine nucleotide; beta-nicotinamide adenine dinucleotide;NAD; NAD+; Nadidum; Nicotinamide; adenine dinucleotide
Cat No.:V30233 Purity: ≥98%
NAD+ is a naturally occurringcoenzyme,oxidizing agent, and electron acceptorconsisting of ribosylnicotinamide 5-diphosphate coupled to adenosine 5-phosphate by a pyrophosphate linkage.
NAD+
NAD+ Chemical Structure CAS No.: 53-84-9
Product category: Endogenous Metabolite
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
500mg
1g
5g
10g
Other Sizes

Other Forms of NAD+:

  • NAD+-13C5 ammonium (nicotinamide adenine dinucleotide-13C5)
  • NAD+-d4 (β-DPN-d4; β-NAD-d4; β-Nicotinamide Adenine Dinucleotide-d4)
  • NAD+-13C5-1 (nicotinamide adenine dinucleotide-13C5-1)
  • NAD+ lithium (nicotinamide adenine dinucleotide lithium salt; β-DPN lithium; β-NAD lithium; β-Nicotinamide Adenine Dinucleotide lithium)
  • NAD Trihydrate
  • NAD sodium (β-DPN sodium; β-NAD sodium; β-Nicotinamide Adenine Dinucleotide sodium)
  • NADH
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Purity: ≥98%

Purity: ≥99%

Purity: ≥98%

Product Description

NAD+ is a naturally occurring coenzyme, oxidizing agent, and electron acceptor consisting of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by a pyrophosphate linkage.

Biological Activity I Assay Protocols (From Reference)
Targets
Endogenous Metabolite
ln Vitro
NAD+ is a coenzyme made up of pyrophosphate bonds connecting adenosine 5'-phosphate and ribosyl nicotinamide 5'-diphosphate. The oxidized form of NADH is called NAD+ [1]. Widespread throughout nature, NAD+ serves as an electron carrier in numerous enzymatic activities by alternating between oxidation (NAD+) and reduction (Nadide) [2].
ln Vivo
Oral NAD+ supplements have been utilized to treat energy-draining, unexplained diseases like fibromyalgia and chronic fatigue syndrome, as well as simple weariness [3].
Enzyme Assay
Redox Titrations Using NADH and NAD+. [3]
NADH was repurified in a glovebox (O2 < 2 ppm) by anion exchange chromatography (5-ml HiTrap Q-Sepharose column) to remove contaminating NAD+. After experimentation, the integrity of the NADH stock solution was reevaluated (0.08 ± 0.04% NAD+ formed in 6 h). Typically, redox potentials were set by using 30 μM NADH and a varying amount of NAD+ (Sigma), and the low potential limit was checked by using the NADH regenerating system.

EPR.[3]
Complex I (10 mg ml−1) was reduced anaerobically by 1 mM purified NADH or by dialysis against purified NADH (≈−0.4 V) or to ≈−0.3 V by using 1 mM NADH and 10 mM NAD+, and frozen immediately. Spectra were recorded on a Bruker EMX X-band spectrometer by using an ER 4119HS high-sensitivity cavity and a ESR900 continuous-flow liquid helium cryostat [3].
Animal Protocol
NADH:ubiquinone oxidoreductase (complex I) is a major source of reactive oxygen species in mitochondria and a significant contributor to cellular oxidative stress. Here, we describe the kinetic and molecular mechanism of superoxide production by complex I isolated from bovine heart mitochondria and confirm that it produces predominantly superoxide, not hydrogen peroxide. Redox titrations and electron paramagnetic resonance spectroscopy exclude the iron-sulfur clusters and flavin radical as the source of superoxide, and, in the absence of a proton motive force, superoxide formation is not enhanced during turnover. Therefore, superoxide is formed by the transfer of one electron from fully reduced flavin to O2. The resulting flavin radical is unstable, so the remaining electron is probably redistributed to the iron-sulfur centers. The rate of superoxide production is determined by a bimolecular reaction between O2 and reduced flavin in an empty active site. The proportion of the flavin that is thus competent for reaction is set by a preequilibrium, determined by the dissociation constants of NADH and NAD+, and the reduction potentials of the flavin and NAD+. Consequently, the ratio and concentrations of NADH and NAD+ determine the rate of superoxide formation. This result clearly links our mechanism for the isolated enzyme to studies on intact mitochondria, in which superoxide production is enhanced when the NAD+ pool is reduced. Therefore, our mechanism forms a foundation for formulating causative connections between complex I defects and pathological effects.[3]
Toxicity/Toxicokinetics
mouse LD50 intraperitoneal 4333 mg/kg Pharmaceutical Chemistry Journal, 20(160), 1986
References

[1]. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond), 2012. 122(6): p. 253-70.

[2]. Brandt, U., Energy converting NADH:quinone oxidoreductase (complex I). Annu Rev Biochem, 2006. 75: p. 69-92.

[3]. Kussmaul, L. and J. Hirst, The mechanism of superoxide production by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc Natl Acad Sci U S A, 2006. 103(20): p. 7607-12.

Additional Infomation
NAD zwitterion is a NAD. It has a role as a geroprotector. It is functionally related to a deamido-NAD zwitterion. It is a conjugate base of a NAD(+).
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Nadide has been reported in Homo sapiens with data available.
Nadide is a dinucleotide of adenine and nicotinamide. It has coenzyme activity in redox reactions and also acts as a donor of ADP-ribose moieties.
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C21H27N7O14P2.3H2O
Molecular Weight
717.47
Exact Mass
663.109
Elemental Analysis
C, 38.02; H, 4.10; N, 14.78; O, 33.76; P, 9.34
CAS #
53-84-9
Related CAS #
NAD+-13C5 ammonium;NAD+-d4;NAD+-13C5-1;1859096-06-2;NAD+ lithium;64417-72-7; 53-84-9 (free acid); 20111-18-6 (sodium); 58-68-4 (reduced)
PubChem CID
5892
Appearance
White to off-white solid
Melting Point
140 - 142ºC
Source
Gut microbial/endogenous metabolite
LogP
-5.72
Hydrogen Bond Donor Count
7
Hydrogen Bond Acceptor Count
18
Rotatable Bond Count
11
Heavy Atom Count
44
Complexity
1120
Defined Atom Stereocenter Count
8
SMILES
P(=O)(O[H])(OP(=O)([O-])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])([N+]2=C([H])C([H])=C([H])C(C(N([H])[H])=O)=C2[H])O1)O[H])O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3=C(N([H])[H])N=C([H])N=C23)O1)O[H])O[H]
InChi Key
BAWFJGJZGIEFAR-NNYOXOHSSA-N
InChi Code
InChI=1S/C21H27N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-4,7-8,10-11,13-16,20-21,29-32H,5-6H2,(H5-,22,23,24,25,33,34,35,36,37)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
Chemical Name
1-((2R,3R,4S,5R)-5-((((((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-carbamoylpyridin-1-ium
Synonyms
β-DPNNSC-20272; Nadide; NSC 20272; NSC20272; beta-NAD; beta NAD; Enzopride Nadida; Codehydrase I; nadide; 53-84-9; NAD+; coenzyme I; beta-NAD; Codehydrogenase I; diphosphopyridine nucleotide; beta-nicotinamide adenine dinucleotide;NAD; NAD+; Nadidum; Nicotinamide; adenine dinucleotide
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
H2O : ~41.67 mg/mL (~62.81 mM)
Solubility (In Vivo)
Solubility in Formulation 1: 100 mg/mL (150.73 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.3938 mL 6.9689 mL 13.9379 mL
5 mM 0.2788 mL 1.3938 mL 2.7876 mL
10 mM 0.1394 mL 0.6969 mL 1.3938 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue
CTID: NCT06627868
Phase: N/A
Status: Not yet recruiting
Date: 2024-10-04
The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT
CTID: NCT06558253
Phase: Phase 1
Status: Recruiting
Date: 2024-08-16
IV Administration of ChromaDex's Niagen® as Compared to NAD+
CTID: NCT06382688
Phase: N/A
Status: Active, not recruiting
Date: 2024-04-24
Small Sample,Unicentric,Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss
CTID: NCT05849519
Phase: Early Phase 1
Status: Unknown status
Date: 2023-05-09
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
CTID: NCT04604704
Phase: Phase 2
Status: Completed
Date: 2023-01-25
Contact Us